FDMT (NASDAQ) - 4D Molecular Therapeutics Inc

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US35104E1001
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California. Web URL: https://www.4dmoleculartherapeutics.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for FDMT (NASDAQ) - 4D Molecular Therapeutics Inc


Market Cap in USD 669m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2020-12-11


Fundamental -
Dividend -
Performance 5y -5.06
Rel. Performance vs Sector -2.75
Analysts 4.38
Fair Price Total Ret. 10.37
Fair Price DCF todo


Growth TTM 41.92%
CAGR 5y -34.00%
CAGR / Mean Drawdown 5y -0.58
Sharpe Ratio TTM 0.40
Alpha vs SP500 TTM 0.84
Beta vs SP500 5y weekly 2.09
CAPM 9.78%
Average Daily Range 2m 4.62%
Reversal Oscillator 4.40
Volatility GJR Garch 1y 62.56%
Price / SMA 50 -21.61%
Price / SMA 200 -31.11%
Current Volume 451k
Average Volume 20d 390k


Yield TTM 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Consistency of Dividends all time 0.0%